Large scale isolation of human blood monocytes by continuous flow centrifugation leukapheresis and counterflow centrifugation elutriation for adoptive cellular immunotherapy in cancer patients.
The increasing interest in mononuclear phagocytes for adoptive cellular immunotherapy (ACI) trials in cancer patients led us to define a procedural approach to harvest reproducibly highly purified single-cell suspensions of large numbers of functional human circulating blood monocytes (Mo). A semiclosed counterflow centrifugal elutriation (CCE) system has been developed, using a new large capacity Beckman JE 5.0 rotor with one interchangeable 40 ml or 5 ml separation chamber, to purify Mo from mononuclear cell (MNC) concentrates of healthy donors and cancer patients obtained by continuous flow centrifugation leukapheresis (CFCL). This method does not require a Ficoll density gradient centrifugation step. A total of 115 leukapheresis procedures were carried out in 35 patients and in 30 healthy donors by either Cobe 2997 or Cobe Spectra, with a similar efficiency in MNC apheresis. The average yield per leukapheresis procedure was 5.6 x 10(9) MNC of purity 90-100% (25-45% Mo, 40-65% lymphocytes). The average yields per elutriation procedure (R/O fraction) were 1.1 x 10(9) cells (purity 93% Mo) using the 5 ml separation chamber, and 1.5 x 10(9) cells (purity 91%) using the 40 ml separation chamber, with a respective recovery of 82 +/- 7% and 78 +/- 8% Mo. In vitro analysis of the viability and function of the purified Mo shows that neither morphological integrity nor physiological activity was compromised by this two-step isolation procedure, which additionally provides highly purified human Mo suspensions, in a quantity suitable for ACl of cancer patients.
Faradji
A
A
Département d'Onco-Hématologie, Hôpitaux Universitaires de Strasbourg, France.
Bohbot
A
A
Schmitt-Goguel
M
M
Siffert
J C
JC
Dumont
S
S
Wiesel
M L
ML
Piemont
Y
Y
Eischen
A
A
Bergerat
J P
JP
Bartholeyns
J
J
D002469:Cell Separation / Q000379:methods; D002470:Cell Survival; D002498:Centrifugation / Q000379:methods; D006801:Humans; D007111:Immunity, Cellular; D007116:Immunization, Passive; D016219:Immunotherapy, Adoptive / Q000379:methods*; D007937:Leukapheresis / Q000379:methods*; D009000:Monocytes / Q000166:cytology*; D009369:Neoplasms / Q000628:therapy